About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Cebpb
CCAAT/enhancer binding protein beta
MGI:88373
145 phenotypes from 13 alleles in 18 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Cebpbtm1.1Acle/Cebpb+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 		abnormal skeleton morphology J:150006
Cebpbtm1.1Acle/Cebpbtm1.1Acle
involves: 129P2/OlaHsd * BALB/c * C57BL/6 		abnormal bone trabecula morphology J:150006
abnormal osteoblast physiology J:150006
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
enhanced osteoblast differentiation J:150006
increased bone mineralization J:150006
increased bone ossification J:150006
increased bone resorption J:150006
increased bone trabecula number J:150006
increased bone volume J:150006
prenatal lethality, incomplete penetrance J:150006
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz
Lyz2em1.1(cre)Elgaz/Lyz2+
BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz/Elgaz 		abnormal myeloid cell number J:247885
decreased circulating interleukin-10 level J:247885
decreased susceptibility to bacterial infection J:247885
decreased susceptibility to bacterial infection induced morbidity/mortality J:247885
decreased transforming growth factor beta level J:247885
increased circulating interleukin-6 level J:247885
increased circulating tumor necrosis factor level J:247885
Cebpbtm1.1Maka/Cebpbtm1.1Maka
Tg(Ins2-cre)23Herr/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J 		normal homeostasis/metabolism phenotype J:156725
increased insulin secretion J:156725
Cebpbtm1Aki/Cebpbtm1Aki
involves: 129P2/OlaHsd * C57BL/6 		abnormal macrophage physiology J:153025
abnormal T-helper 1 physiology J:153025
decreased susceptibility to endotoxin shock J:153025
granulomatous inflammation J:153025
increased susceptibility to bacterial infection J:153025
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT5-cre)5132Jlj/?
involves: 129S1/Sv * C57BL/6J * DBA/2J 		decreased incidence of tumors by chemical induction J:107334
increased keratinocyte apoptosis J:107334
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S1/Sv * C57BL/6 * CD-1 		abnormal keratinocyte differentiation J:158721
epidermal hyperplasia J:158721
increased keratinocyte proliferation J:158721
normal integument phenotype J:158721
thick epidermis J:158721
Cebpbtm1Kish/Cebpb+
involves: 129P2/OlaHsd 		abnormal skeletal muscle mass J:237461
Cebpbtm1Kish/Cebpbtm1Kish
involves: 129P2/OlaHsd 		abnormal brown adipose tissue morphology J:45062
abnormal cell differentiation J:45062
abnormal clavicle morphology J:237461
abnormal macrophage physiology J:77003
abnormal thoracic cage morphology J:237461
abnormal zygomatic arch morphology J:237461
female infertility J:45062
impaired macrophage phagocytosis J:77003
increased interleukin-12 secretion J:126085
increased susceptibility to bacterial infection J:77003
neonatal lethality, incomplete penetrance J:45062
perinatal lethality, incomplete penetrance J:77003
postnatal lethality, incomplete penetrance J:45062, J:77003
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * C57BL/6 * FVB 		normal homeostasis/metabolism phenotype J:153686
normal muscle phenotype J:153686
Cebpbtm1Pfj/Cebpb+
B6.Cg-Cebpbtm1Pfj 		decreased incidence of tumors by chemical induction J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
B6.Cg-Cebpbtm1Pfj 		decreased incidence of induced tumors J:73558
decreased incidence of tumors by chemical induction J:73558
increased keratinocyte apoptosis J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
either: 129S1/SvImJ-Cebpbtm1Pfj or (involves: 129S1/SvImJ * C57BL/6) 		abnormal branching of the mammary ductal tree J:48514
abnormal lactation J:48514
abnormal mammary gland development J:48514
Cebpbtm1Pfj/Cebpbtm1Pfj
involves: 129S1/Sv * C57BL/6 		abnormal osteoblast physiology J:150006
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
abnormal skeleton morphology J:150006
abnormal tumor necrosis factor level J:192313
absent corpus luteum J:43075
absent estrous cycle J:43075
decreased bone mineralization J:150006
decreased bone ossification J:150006
decreased bone trabecula number J:150006
decreased bone volume J:150006
decreased superovulation rate J:43075
decreased trabecular bone thickness J:150006
female infertility J:43075
impaired granulosa cell differentiation J:43075
impaired luteinization J:43075
impaired ovarian folliculogenesis J:43075
increased bone resorption J:150006
prenatal lethality, incomplete penetrance J:43075, J:150006
normal reproductive system phenotype J:43075
Cebpbtm1Vpo/Cebpb+
involves: 129S/SvEv * C57BL/6 * MF1 		abnormal mammary gland duct morphology J:48513
Cebpbtm1Vpo/Cebpbtm1Vpo
FVB.129S-Cebpbtm1Vpo 		decreased sensitivity to induced cell death J:52729
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6 		abnormal brown adipose tissue physiology J:117502
decreased body weight J:117502
decreased brown adipose tissue amount J:117502
decreased epididymal fat pad weight J:117502
decreased lipoprotein lipase activity J:117502
decreased triglyceride level J:117502
impaired adaptive thermogenesis J:117502
increased circulating glucose level J:117502
increased circulating triglyceride level J:117502
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6 * MF1 		abnormal branching of the mammary ductal tree J:48513
abnormal gluconeogenesis J:49673
abnormal glucose homeostasis J:49673
abnormal mammary gland development J:48513
abnormal mammary gland duct morphology J:48513
abnormal mammary gland epithelium physiology J:48513
female infertility J:48513
hypoglycemia J:49673
impaired liver regeneration J:49673
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * MF1 		abnormal adipose tissue physiology J:52286
abnormal cell-mediated immunity J:25215
abnormal circulating free fatty acids level J:52286
abnormal definitive hematopoiesis J:25215
abnormal enzyme/coenzyme level J:52286
abnormal gluconeogenesis J:52286
abnormal glucose homeostasis J:52286, J:62132
abnormal humoral immune response J:25215
abnormal innate immunity J:25215
abnormal lipid homeostasis J:52286, J:62132
abnormal lymph node B cell domain morphology J:25215
abnormal lymph node cortex morphology J:25215
abnormal lymph node medulla morphology J:25215
abnormal lymph node medullary cord morphology J:25215
abnormal lymph node secondary follicle morphology J:25215
abnormal lymph node T cell domain morphology J:25215
abnormal macrophage physiology J:25215
abnormal mucosa-associated lymphoid tissue morphology J:25215
abnormal plasma cell morphology J:25215
abnormal spleen red pulp morphology J:25215
abnormal spleen secondary B follicle morphology J:25215
abnormal spleen white pulp morphology J:25215
abnormal T-helper 1 physiology J:25215
abnormal T-helper 2 physiology J:25215
decreased circulating free fatty acids level J:52286, J:62132
decreased circulating insulin level J:62132
decreased circulating interleukin-12 level J:25215
decreased circulating leptin level J:62132
decreased circulating triglyceride level J:52286
decreased glycogen catabolism rate J:52286
decreased gonadal fat pad weight J:62132
decreased percent body fat/body weight J:62132
decreased susceptibility to type IV hypersensitivity reaction J:25215
decreased uterine fat pad weight J:52286
enlarged axillary lymph nodes J:25215
enlarged inguinal lymph nodes J:25215
enlarged lymph nodes J:25215
enlarged mesenteric lymph nodes J:25215
enlarged spleen J:25215
enlarged submandibular lymph nodes J:25215
expanded mesangial matrix J:25215
extramedullary hematopoiesis J:25215
glomerulonephritis J:25215
hemosiderosis J:25215
hypoglycemia J:52286, J:62132
impaired lipolysis J:62132
increased bone marrow cell number J:25215
increased circulating corticosterone level J:52286
increased circulating interleukin-6 level J:25215
increased IgG level J:25215
increased insulin sensitivity J:62132
increased mesangial cell number J:25215
increased skeletal muscle cell glucose uptake J:62132
increased susceptibility to fungal infection J:25215
postnatal lethality, incomplete penetrance J:25215
premature death J:25215
renal glomerulus hypertrophy J:25215
skin lesions J:25215
Cebpbtm2.1Acle/Cebpbtm2.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 		abnormal osteoclast morphology J:155795
decreased cell proliferation J:155795
decreased osteoclast cell number J:155795
impaired liver regeneration J:155795
increased bone volume J:155795
increased circulating interleukin-6 level J:155795
increased trabecular bone thickness J:155795
normal reproductive system phenotype J:155795
Cebpbtm3.1Acle/Cebpbtm3.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 		no abnormal phenotype detected J:155795
Cebpbtm3Nerl/Cebpbtm3Nerl
either: B6.129P2-Cebpbtm3Nerl or (involves: 129P2/OlaHsd * C57BL/6) 		calcified muscle J:153686
decreased skeletal muscle fiber size J:153686
impaired skeletal muscle regeneration J:153686
increased physiological sensitivity to xenobiotic J:153686
myositis J:153686
normal reproductive system phenotype J:153686
skeletal muscle fibrosis J:153686
Tg(Ins2-Cebpb)2Maka/0
involves: C57BL/6 		abnormal pancreas physiology J:156725
decreased circulating insulin level J:156725
decreased insulin secretion J:156725
decreased pancreatic beta cell mass J:156725
increased circulating glucose level J:156725
increased pancreatic islet cell apoptosis J:156725
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/05/2024
MGI 6.24 		The Jackson Laboratory